What's going on with the NIB share price today?

We now know when the private health insurer's long-serving CEO is stepping down.

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is underperforming on Thursday morning.

At the time of writing, the private health insurance provider's shares are trading largely flat.

As a comparison, the ASX 200 index is up 0.65%.

Why is the NIB share price underperforming?

The catalyst for this underperformance has been confirmation that the company's long-serving managing director and CEO is stepping down in a touch over two months.

According to the release, Mark Fitzgibbon will formally resign from the role on 30 November. Mr Fitzgibbon joined NIB in 2002 as its leader and took the company through its demutualisation and listing on the ASX in 2007.

It is worth noting that this isn't brand new information. In July, the company revealed that Fitzgibbon was planning to hand in his resignation in September.

At the time, the company stated:

From modest beginnings in 1952, today nib provides more than 1.6 million Australian and New Zealand residents with private health insurance; it looks after the health and wellbeing needs of more than 200,000 international students and workers; nib is Australia's third-largest travel insurer, a 24-7 global business; and it helps around 40,000 participants in Australia's disability sector. For the last 22 years, Mark has been at the helm of a company that has undergone a remarkable transformation, and that transformation is a great credit to his leadership.

New CEO

Replacing Mark Fitzgibbon will be Ed Close. He is currently chief executive of NIB's core Australian Residents Health Insurance (arhi) business. In this role, Close oversees product development, claims, customer services, and leads NIB's strategic partnerships with brokers and white label partners.

NIB chair, David Gordon, described Ed Close as an "exceptional leader" and "able to bring NIB's strategy to life and deliver continued strong growth."

Should you invest?

Goldman Sachs is feeling positive about NIB and sees value in its share price.

According to a recent note, the broker has a buy rating and $6.60 price target on the company's shares.

Commenting on its buy rating, the broker said:

NHF is a private health insurer with operations across Australian residents health insurance, New Zealand health insurance, International health insurance and Travel. We are Buy-rated on NHF given: 1) It offers defensive exposure to the private health insurance sector 2) The claims environment (utilisation / inflation) has been relatively manageable 3) NHF policyholder growth has been better than industry, 4) Expense buffers available to support margins and 5) Strong approved rate increases.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

healthcare worker overseeing group of aged care residents at table
Share Gainers

This ASX All Ords share has sneakily climbed 128% over the past year

Investors have sent this under-the-radar ASX All Ords stock flying higher. But why.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

UBS says buy CSL shares for a double-digit return in 2025

This ASX giant could create healthy returns, according to a leading broker.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

1 big factor to keep in mind before buying Pro Medicus shares

Investors would be wise to consider this metric.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

ASX All Ords share higher despite major shareholder cashing out 30% stake

Investors in this ASX All Ords healthcare share appear unperturbed by news of a major sell-down.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Healthcare Shares

Up 24% in a month! This ASX biotech share is hitting a record high on trial update

The SECuRE trial is getting investors excited. Here's the latest.

Read more »

2 people using their iPhones
Healthcare Shares

Did Apple just give ResMed shares a big long-term boost?

Is awareness of sleep apnoea about to increase materially?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Are Pro Medicus shares a buy at their new all-time high?

Investors continue lifting the bid on this healthcare player.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Why are CSL shares trading in the red today?

The biotech hasn't posted anything sensitive.

Read more »